Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 473 All time
- Disclosed funding
- $19.6B 400 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| O Develops AI-based predictive genomics approach to target discovery | £2.5M | Seed | Biotech | United Kingdom | Investors | |
| KT Develops inhaled therapies for severe respiratory diseases | $103M | Series B | Biotech | United States | Investors | |
| M MEDIPOSTCompany profile MEDIPOST develops stem-cell therapies derived from donated umbilical cord blood. MEDIPOST develops stem-cell therapies derived from donated umbilical cord blood. | $140M | Undisclosed | Biotech | United States | Investors | |
| b bit.bioCompany profile Creates functional, human-relevant cells and models for research, drug discovery, and development Creates functional, human-relevant cells and models for research, drug discovery, and development | $50M | Series CSeries C+ | Biotech | United Kingdom | Investors | |
| AT AirNexis TherapeuticsCompany profile AirNexis Therapeutics develops medicines for pulmonary diseases, led by the investigational COPD candidate AN01. AirNexis Therapeutics develops medicines for pulmonary diseases, led by the investigational COPD candidate AN01. | $200M | Series A | Biotech | United States | Investors | |
| V Builds technologies for spatial biology and multi-omics innovation | $48M | Series A | Biotech | United States | Investors | |
| A AbbelightCompany profile Microscopy and nanoscopy systems combining chemistry, optics and analysis for life-science researchers. Microscopy and nanoscopy systems combining chemistry, optics and analysis for life-science researchers. | Undisclosed | Series B | Biotech | France | Investors | |
| ET Enodia TherapeuticsCompany profile Develops small-molecule therapies for targeted protein degradation at the point of synthesis Develops small-molecule therapies for targeted protein degradation at the point of synthesis | €20.7M | Seed | Biotech | France | Investors | |
| E EpiBiologicsCompany profile Develops bispecific antibodies for targeted degradation of extracellular proteins. Develops bispecific antibodies for targeted degradation of extracellular proteins. | $107M | Series B | Biotech | United States | Investors | |
| PD Perceptive DiscoveryCompany profile Provides preclinical and translational solutions for oncology and radiopharmaceutical programs Provides preclinical and translational solutions for oncology and radiopharmaceutical programs | $15M | StrategicUndisclosed | Biotech | United Kingdom | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.